Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Debt to Equity (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Debt to Equity for 9 consecutive years, with $0.33 as the latest value for Q4 2025.

  • On a quarterly basis, Debt to Equity rose 476.84% to $0.33 in Q4 2025 year-over-year; TTM through Dec 2025 was $0.33, a 476.84% increase, with the full-year FY2025 number at $0.33, up 476.84% from a year prior.
  • Debt to Equity was $0.33 for Q4 2025 at Myriad Genetics, up from $0.32 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.33 in Q4 2025 to a low of $0.05 in Q4 2023.
  • A 4-year average of $0.11 and a median of $0.06 in 2024 define the central range for Debt to Equity.
  • Peak YoY movement for Debt to Equity: soared 3316.86% in 2021, then fell 5.39% in 2024.
  • Myriad Genetics' Debt to Equity stood at $0.12 in 2021, then crashed by 57.39% to $0.05 in 2023, then grew by 14.9% to $0.06 in 2024, then soared by 476.84% to $0.33 in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Debt to Equity are $0.33 (Q4 2025), $0.32 (Q3 2025), and $0.15 (Q2 2025).